Lamotrigine can be beneficial in patients with Dravet syndrome

Developmental Medicine and Child Neurology

Volumn 57, Issue 2, 2015, Pages 200-202

  Dalic, Linda ^a   Mullen, Saul A ^a,b   Roulet Perez, Eliane ^c   Scheffer, Ingrid ^b  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; LAMOTRIGINE; TRIAZINE DERIVATIVE;

ADOLESCENT; ADULT; CASE REPORT; EPILEPSIES, MYOCLONIC; HUMAN; MALE; PATHOPHYSIOLOGY; SEIZURES;

ADOLESCENT; ADULT; ANTICONVULSANTS; EPILEPSIES, MYOCLONIC; HUMANS; MALE; SEIZURES; TRIAZINES;

EID: 84921932473     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/dmcn.12593     Document Type: Article

References (14)

1. Dravet C, Bureau M, Oguni H, Cokar O, Guerrini R. Dravet syndrome (Severe myoclonic epilepsy in infancy). In: Bureau M, Genton P, Dravet C, Delgado-Escueta A, Tassinari CA, Thomas P, Wolf P, editors. Epileptic Syndromes in Infancy, Childhood and Adolescence. 5th edn. Montrouge, France: John Libbey Eurotext, 2012: 125-56.
2. Catarino C, Liu JY, Liagkouras I, et al. Dravet syndrome as epileptic encephalopathy: evidence from long-term course and neuropathology. Brain 2011; 134: 2982-3010.
3. Akiyama M, Kobayashi K, Yoshinaga H, Ohtsuka Y. A long-term follow-up study of Dravet syndrome up to adulthood. Epilepsia 2010; 51: 1043-52.
4. Jansen FE, Sadleir LG, Harkin LA, et al. Severe myoclonic epilepsy of infancy (Dravet syndrome): recognition and diagnosis in adults. Neurology 2006; 67: 2224-6.
5. Depienne C, Trouillard O, Saint-Martin C, et al. Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients. J Med Genet 2009; 46: 183-91.
6. Harkin L, McMahon J, Iona X, et al. The spectrum of SCN1a-related infantile epileptic encephalopathies. Brain 2007; 130: 843-52.
7. Zuberi SM, Brunklaus A, Birch R, Reavey E, Duncan J, Forbes GH. Genotype-phenotype associations in SCN1A-related epilepsies. Neurology 2011; 76: 594-600.
8. Chiron C, Dulac O. The pharmacologic treatment of Dravet syndrome. Epilepsia 2011; 52: 72-5.
9. Ceulemans B, Boel M, Leyssens K, et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia 2012; 53: 1131-9.
10. Nabbout R, Chemaly N, Chipaux M, et al. Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy. Orphanet J Rare Dis 2013; 8: 176.
11. Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998; 39: 508-12.
12. Bialer M. Chemical properties of antiepileptic drugs (AEDs). Adv Drug Deliv Rev 2012; 64: 887-95.
13. Postea O, Biel M. Exploring HCN channels as novel drug targets. Nat Rev 2011; 10: 903-14.
14. Le Gal F, Lebon S, Ramelli GP, et al. When is a child with status epilepticus likely to have Dravet syndrome? Epilepsy Res 2014; 108: 740-7.